Flow Cytometry Market To Surpass US$ 9.3 Billion By 2027| Coherent Market Insights

 

Flow Cytometry Market

The need for disease diagnosis and progress in flow cytometry technology are both anticipated to fuel market growth over the forecast period. To reach the emerging markets, manufacturers are concentrating on technological advancements in flow cytometry. For instance, in August 2017, the U.S. Food and Drug Administration (FDA) approved Beckman Coulter Life Sciences' most recent clinical flow cytometry product, the Navios EX flow cytometer, for use in clinical laboratories in the United States. In addition, as part of its mission to provide cutting-edge clinical laboratory products, Sysmex America, Inc. introduced CyFlow Antibodies in October 2017—a comprehensive portfolio of Analyte Specific Reagent (ASR) antibodies for use in flow cytometry applications.

Major players are also concentrating on product launches in order to diversify their product offerings and to improve their market positions. For instance, Becton, Dickinson and Company (US) released its FlowJo software version 10.6 in June 2019 for the analysis of flow cytometry data. This software can be further integrated with BD FACSDiva to increase its capabilities for the comparison of data from various flow cytometry runs in a single view and the analysis of multiple flow cytometry runs.

In 2018, The Flow Cytometry Market Was Valued At US$3,886.1 Million, And It Is Anticipated To Grow At A CAGR Of 10.2% Between 2018 And 2023. (2019-2027).

Analyzing the expression of cell surface and intracellular molecules is made easier by flow cytometry. It helps evaluate the purity of isolated subpopulations and is used to define and characterise various types of cells in a heterogeneous cell population. The market is being driven by increased R&D efforts by several key players for the creation of multicolor assays and cutting-edge analytical reagents. The market for flow cytometry has experienced rapid growth as a result of the rising prevalence of chronic and infectious diseases, including the COVID-19 outbreak. Following the outbreak, a large number of academic institutions and pharmaceutical firms are engaged in extensive research and development (R&D) activities for the creation of new vaccines and treatments. Due to this, there is a great need for flow cytometry applications in research.

Cancer and immunodeficiency are two conditions that are frequently diagnosed using flow cytometry. One of the elements anticipated to propel the market for flow cytometry over the forecast period is the rising prevalence of these diseases. Additionally, the negative effects of chemotherapy and radiation therapy in the treatment of cancer have led doctors to prefer autologous and allogeneic stem cell therapies more, positively influencing the development of this market.

Due to rising healthcare costs in developed nations and bettering healthcare infrastructure, the biotechnology industry is anticipated to experience significant growth during the forecast period. The market is anticipated to be driven by an increase in government funding for clinical studies involving in vitro molecular diagnostics, as these studies are essential to the creation of new products. Significant market growth has been fueled by rising investments in well-known biotech and biopharma companies.

Top companies involved are- Becton Dickinson and Company, General Electric Company, Luminex Corporation, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Miltenyi Biotec GmbH, Merck & Co Inc., Sysmex Corporation, Agilent Technologies, Inc., and Danaher Corporation.

 

Get Press Release of Flow Cytometry Market

Comments

Popular posts from this blog

Ginseng Market Outlook, Analysis and forecast up to 2028

Forging has significant application in creation of various metal for wide range of applications

The Vaccine Contract Manufacturing Industry to Flourish Due to Urgent Need to Develop Reliable and Cost-Effective Vaccines against Covid-19